Embedded Files
The Preclinical neuroImaging Lab (PILab) is a multidisciplinary team focused on translational research in central nervous system disorders. Our work combines advanced imaging techniques, magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET), to develop and validate biomarkers that support diagnosis, prognosis, and the evaluation of novel therapies.
Non-invasive preclinical imaging is our main tool, as it provides quantitative and functional information that can be directly transferred to clinical practice.
Main Research Lines
Main Research Lines
Multiparametric characterization of the tumor microenvironment in high-grade gliomas.
We study high-grade gliomas using animal models and advanced imaging approaches, aiming to identify biomarkers and validate new therapeutic strategies. Our focus includes:
Glioblastoma (GBM): The most common and aggressive primary brain tumor, with a median survival of only 14–19 months. We investigate multiparametric imaging markers to establish robust correlations with histological and molecular findings.
Anaplastic astrocytoma: Characterized by intermediate aggressiveness and a median survival of 3–6 years. We are developing imaging protocols to non-invasively detect key molecular prognostic markers and thereby support improved therapeutic stratification.
Diffuse midline gliomas (GDLM): Highly aggressive tumors with a median survival below one year. Our research focuses on imaging biomarkers to monitor treatment response and enable early detection of tumor progression.
Neuroinflammation biomarkers through MRI/MRS/PET.
Neuroinflammation is a critical component of many neurological diseases, yet its precise characterization remains challenging. We develop multiparametric MRI/MRS/PET methodologies to objectively quantify inflammatory processes in animal models, supporting the evaluation of therapeutic efficacy and the exploration of novel therapeutic targets.Development of theranostic compounds based on nanomedicine.
We design and validate innovative theranostic compounds in preclinical models. These nanomedicine-based systems are engineered to cross the blood–brain barrier, selectively target tumor cells, and combine diagnostic and therapeutic functions within a single platform. This approach offers significant potential for precision medicine in the context of high-grade gliomas.Design of Tools for Processing, Analysis, and Classification of Brain Imaging Data.
We develop tools based on artificial intelligence and radiomics methodologies for advanced analysis of brain imaging data. This research line is carried out in collaboration with Hospital Universitario La Paz, using images from human patients with the aim of generating predictive models and classification algorithms that facilitate clinical stratification and enhance the translation of biomedical imaging into clinical practice.
Translational Impact
Translational Impact
Our research is aimed at developing diagnostic and therapeutic tools with clear clinical applicability. We contribute to the advancement of personalized neuro-oncology by identifying predictive biomarkers, optimizing imaging protocols, and validating innovative therapies in preclinical models that closely reflect human disease.
Page updated
Google Sites
Report abuse